e-ISSN: 3108-3218

BTS International Advanced Pharmaceutical Sciences Journal

Vol 01 | Issue 06 | JUNE 2026 Journal homepage: www.btsempire.com

ARTICLE ID: BTS0626002

BONE TURNOVER MARKERS IN OSTEOPOROSIS: CLINICAL RELEVANCE IN FRACTURE PREDICTION AND MANAGEMENT

Sai Rohith P | Triveni R

KVSR Siddhartha College of Pharmaceutical Sciences, Vijayawada, Andhra Pradesh, India.
Corresponding Mail ID: sairohithpadamata04@gmail.com

RECEIVED: 31 August 2025 | **REVISED & ACCEPTED:** 05 November 2025

KEYWORDS: Bone turnover markers, Osteoporosis, Fracture risk, Bone remodelling, Diagnosis, Treatment monitoring.

ABSTRACT:
Osteoporosis is a chronic skeletal disease of decreased bone mass and micro architectural deterioration, with an increase in fracture risk and decreased quality of life. Bone turnover markers (BTMs), as indicators of dynamic bone formation and resorption processes, have become useful tools in the pathophysiology of osteoporosis and managing the condition. Bone formation markers such as procollagen type 1 N-terminal pro-peptide (P1NP), bone-specific alkaline phosphatase, and osteocalcin, and resorption markers such as C-terminal telopeptide (CTX), N-terminal telopeptide (NTX), deoxypyridinoline, and tartrate-resistant acid phosphatase 5b provide information about the overall balance of bone re-modelling. These markers are more than just an academic exercise; they have potential clinical nuances as adjunctive information in diagnoses, fracture risk assessment, and as an assessment of the response to antiresorptive or anabolic therapies. Longitudinal studies have established a relationship between increased BTMs and increased bone loss and fracture rates, while BTM changes due to treatment may provide a faster assessment of potential treatment effect and compliance compared to imaging approaches such as dual-energy X-ray absorptiometry (DXA). Preanalytical variability, non-standardization of assays, and limited accessibility limit their widespread use. Future integration with imaging equipment, FRAX, and personalized medicine strategies can increase the accuracy in risk stratification, maximize treatment options, and enhance the outcomes of patients. This critique evaluates the clinical significance of BTMs in osteoporosis, highlighting the role in fracture prediction, management, and the direction of ongoing research, in response to current limitations and future outlooks in developing individualized care.

1. INTRODUCTION

1.1 DEFINITION AND IMPORTANCE OF BONE TURNOVER MARKERS (BTMS)

Bone turnover markers (BTMs) are biochemical markers that express the dynamic equilibrium between bone resorption and bone formation and therefore yield excellent information regarding skeletal metabolism. They can be quantitatively measured in urine and blood without invading the tissues, thus serving to be excellent tools for evaluating longitudinal skeletal alterations. Since osteoporosis is a condition that typically results from a pathological long term imbalance in the process of bone remodeling, BTMs are becoming more

© BTS Pharma Empire All Rights Reserved

e-ISSN: 3108-3218

BTS International Advanced Pharmaceutical Sciences Journal

Vol 01 | Issue 06 | JUNE 2026 Journal homepage: www.btsempire.com

ARTICLE ID: BTS0626002

important in both research and clinical practice [0]. Rather than relying on imaging modalities, such as DXA, which assess bone mineral density at one-time point, BTMs provide real-time data on bone metabolic activity. Bone formation and resorption markers (e.g., osteocalcin, procollagen type 1 N-terminal propeptide [P1NP]) and (e.g., C-terminal telopeptide [CTX], N-terminal telopeptide [NTX]) combined enable clinicians to assess the relative balance between osteoblastic and osteoclastic activity, thus giving a better picture of skeletal integrity [0]. In osteoporosis, a faster rate of resorption compared to formation results in bone fragility and increased risk of fracture. Higher levels of bone resorption markers coincide with more bone loss, whereas the fall in resorption markers during treatment is a sign of effective inhibition of osteoclast activity. Anabolic treatments are the opposite effect of the resorption markers, since they are usually increased bone formation markers as a result of stimulation of the pathways activating bone formation. BTMs are therefore not only responsible for the recognition of high-risk fracture patients but also for the planning and follow-up of personalized therapeutic approaches [0].

1.2 BTM'S FUNCTION IN THE TREATMENT OF OSTEOPOROSIS

Bone turnover markers (BTMs) have a supportive function to play in the treatment of osteoporosis by augmenting bone mineral density (BMD) measurements and giving dynamic information on skeletal metabolism. While not diagnostic by themselves, BTMs are useful adjuncts to BMD and assist in the identification of patients with active, high-turnover disease who are most likely to respond to pharmacological treatment. Baseline BTM values not only risk-stratify patients but also can anticipate the size of response to anti-resorptive or anabolic therapy [0]. Further, following therapy, monitoring BTMs makes possible early treatment assessment within weeks to months, as compared to years needed to observe significant BMD change. For example, anti-resorptive treatments usually reduce CTX and NTX by 50–70% within 3–6 months, whereas anabolic treatments usually increase P1NP and osteocalcin. Repeated or irreversible abnormalities of BTM levels can reflect patient non-adherence, secondary osteoporosis, or failure of treatment, requiring early re-evaluation and adjustment of treatment strategies [0].

2.BONE BIOLOGY AND OSTEOPOROSIS

2.1 Bone Remodeling Physiology

Bone remodeling is a tightly regulated ongoing process that supports skeletal strength and mineral homeostasis by the coordinated functions of osteoblasts and osteoclasts. Osteoblast-mediated bone formation consists of synthesis of a matrix rich in collagen followed by deposition of minerals. This activity is induced by growth factors like IGF-1, hormones like estrogen and parathyroid hormone (PTH), and mechanical loading, which collectively are responsible for structural adaptation and microdamage repair [0].Unlike bone formation, bone resorption is controlled by osteoclasts proceeding from hematopoietic precursor cells and utilizing acidification and enzymatic events to dematerialize weight-bearing mineralized bone matrix. The RANK-RANKL-OPG axis drives osteoclast differentiation and regulation and is key in the over-resorption pathophysiology that underwrites osteoporosis in various

© BTS Pharma Empire All Rights Reserved

e-ISSN: 3108-3218

BTS International Advanced Pharmaceutical Sciences Journal

Vol 01 | Issue 06 | JUNE 2026 Journal homepage: www.btsempire.com

ARTICLE ID: BTS0626002

manifestations [0]. The figure-1 shows the bone remodeling cycle, which summarizes the dynamic process of bone renewal and maintenance.



Figure-1: Bone Remodeling Cycle

2.2 pathophysiological basis of osteoporosis

The pathophysiological basis of osteoporosis is a process (i.e., skeletal remodeling) that has a net imbalance with too much resorption of bone without an adequate amount of formation, increasing the risk of skeletal structural failure. As a result of age and reductions in sex hormones (specifically, testosterone in men and estrogen in postmenopausal women), lifelong skeletal remodeling is characterized by an increasing amount of resorption specifically. With reductions in bone formation by osteoblasts on a timeline of months to years, changes to the trabecular microarchitecture and a decrease in the total mass of the cortical skeleton occur. This compromise to both the quality and quantity of bone dramatically increases bone fragility (i.e. the risk for structural failure) and risk for fractures [0]. A significant contributor to this imbalance is the control of hormonal and cytokine signaling. In the setting of estrogen deficiency, the activity of RANKL, IL-1, IL-6, and TNF-α is elevated which contribute to osteoclastogenesis and increases bone resorption while suppressing new osteoblast recruitment and bone formation. The aberrant signaling environment drives net bone loss and represents the pathophysiological basis of osteoporosis [0]. The figure-2 summarizes the pathophysiology of osteoporosis, highlighting the mechanisms that lead to skeletal fragility.



Figure-2: Pathophysiology of Osteoporosis

2.3 Osteoporosis Risk Factors and the Clinical Impact on Quality of Life

Osteoporosis is affected by a number of intrinsic and extrinsic factors that condition skeletal health and increase risk for bone loss and fragile fractures. While genetics contribute significantly, we cannot target the entirety of the intrinsic factors, including polymorphisms in collagen synthesis genes, polymorphisms in a person's vitamin D receptor, and alterations in the RANKL/OPG signaling pathway. Each of these can help explain some of the differences in peak bone mass

© BTS Pharma Empire All Rights Reserved

e-ISSN: 3108-3218

BTS International Advanced Pharmaceutical Sciences Journal

Vol 01 | Issue 06 | JUNE 2026 Journal homepage: www.btsempire.com

ARTICLE ID: BTS0626002

and risk for fractures [0]. Anatomical, lifestyle and environmental factors are important too, especially those that condition some part of the bone physiology such as intakes of calcium and vitamin D, being sedentary, chronic smoking, and excessive alcohol intake because all of these factors condition our skeletal health and quality of life. The extent of the consequences due to this disease goes beyond just bone loss but rather also has a major clinical and psychosocial impact. Examples of osteoporotic fractures associated with clinically significant impacts are hip fractures and spinal fracturing, which can have significant pain, other physical mobility limitations, loss of independence and mortality. The psychosocial burden can also be significantly underestimated as potentially clinically significant. Concurrently there are reductions in self-image/self-esteem, fear of falling, social isolation, and elevated depression rates. As health-care providers, we must consider all these variables when contemplating methods of prevention and subsequent interventions [0].

3.BONE TURNOVER MARKERS

Bone turnover markers (BTMs) are generally classified as bone formation and resorption markers that express osteoblastic and osteoclastic activity, respectively. Of the formation markers, Procollagen Type 1 N-Terminal Propeptide (P1NP) is considered a highly sensitive and specific marker of novel collagen synthesis and bone formation. Identified by international expert groups as a reference marker, P1NP has low variability and good correlation with anabolic activity [0]. Bone-Specific Alkaline Phosphatase (Bone ALP), a matrix mineralization-released isoenzyme, is less vulnerable to short-term variation and has clinical utility in the assessment of osteoporosis and other metabolic bone disease like Paget's disease. Mature osteoblast-secreted osteocalcin is as closely related to bone mineralization as P1NP but its clinical application is marred by the problems of short half-life, vitamin K dependence, and non-standardization of assays in comparison with P1NP [0].

With regard to markers of resorption, C-terminal telopeptide (CTX) is commonly used in the clinic as a sensitive bone resorption and therapy monitoring marker. Yet, its circadian pattern with morning spikes and inhibition by eating requires rigorous sampling schedules N-terminal telopeptide (NTX), which is mostly used in urine, indicates degradation of collagen during bone resorption and can be employed in monitoring response to therapy, although it is more variable than CTX [0] . Deoxypyridinoline (DPD), a particular cross-link produced during the breakdown of collagen and excreted in urine, is very bone resorption-specific but has fallen into disuse clinically due to cumbersome assay procedures and the superior performance of CTX. Lastly, Tartrate-Resistant Acid Phosphatase 5b (TRACP-5b), secreted by osteoclasts in a direct manner, gives a stable osteoclast number and activity index since it is independent of diet or renal function. This renders it more established as a trusted indicator for tracking anti-resorptive therapy [0]. Table-1 provides an overview of bone formation and resorption markers, highlighting their biological significance and clinical application in osteoporosis management.

© BTS Pharma Empire All Rights Reserved

e-ISSN: 3108-3218

BTS International Advanced Pharmaceutical Sciences Journal

Vol 01 | Issue 06 | JUNE 2026 Journal homepage: www.btsempire.com

ARTICLE ID: BTS0626002

Table-1: Overview of Bone Formation and Resorption Markers

Marker Type	Marker	Key Characteristics	Clinical Relevance
Formation	**P1NP**	Sensitive, minimally variable, reflects new collagen synthesis	Standard marker; correlates with anabolic activity
	Bone ALP	Isoenzyme of matrix mineralization, less affected by short-term changes	Valuable in osteoporosis and metabolic bone diseases (e.g., Paget's)
	Osteocalcin	Secreted by mature osteoblasts; linked with mineralization	Limited by short half-life, vitamin K dependence, and poor standardization
Resorption	**CTX**	Sensitive to therapy changes; diurnal rhythm and food-sensitive	Widely used in clinical practice; requires strict sampling conditions
	NTX	Measured mostly in urine; collagen breakdown product	Useful for monitoring therapy but more variable than CTX
	DPD	Collagen cross-link excreted in urine; very specific	Assay complexity has reduced clinical utility
	TRACP-5b	Osteoclast-derived, stable (diet/renal function independent)	Reliable marker for osteoclast activity and therapy monitoring

4. CLINICAL APPLICATION OF BTMS

4.1 Osteoporosis Diagnosis

Bone turnover markers (BTMs) play an important clinical role in supplementing imaging methods by providing insights into the dynamic process of bone remodeling. They can identify metabolic abnormalities prior to the substantial loss of bone mineral density (BMD), providing forward-looking utility in the early stages of disease. Elevated resorption markers such as serum C-terminal telopeptide of type I collagen (s-CTX) along with depressed formation markers such as serum procollagen type I N-terminal propeptide (s-PINP) indicate a pace of loss that increases the risk of osteoporosis or transition from osteopenia [0]. Despite the important metabolic information BTMs provide, they are neither sufficient to establish a definitive diagnosis of osteoporosis, nor to assess fracture risk. Dual-energy X-ray absorptiometry (DXA) remains the gold-standard for diagnosis today because it directly measures bone mineral density. DXA does have important limitations including its inability to assess bone quality or the amount of active turnover. Whereas DXA is a cross-sectional evaluation of skeletal mineralization and density, BTMs can provide a real-time assessment of skeletal metabolism, and reflect changes in bone remodeling often months before imaging changes are detected. Combined, these tools provide clearer diagnosis and allow clinicians to recognize and intercede for patients at risk for reversible skeletal damage earlier [0].

4.2 Fracture Risk Assessment

© BTS Pharma Empire All Rights Reserved

e-ISSN: 3108-3218

BTS International Advanced Pharmaceutical Sciences Journal

Vol 01 | Issue 06 | JUNE 2026 Journal homepage: www.btsempire.com

ARTICLE ID: BTS0626002

Bone turnover markers (BTMs) such as the resorption marker s-CTX are independent predictors of fracture risk, for vertebral, non-vertebral, and hip fractures. BTMs are beneficial in cases of borderline BMD where the DXA result may not provide a complete risk assessment. As with fracture risk, the predictive nature of BTMs increases when used in conjunction with clinical factors (e.g., age, sex, menopausal status, glucocorticoid therapy, smoking or family history) to support FRAX and inform risk stratification into low, intermediate and high [0].

4.3 Monitoring Treatment Effect

BTMs are helpful for providing early feedback on treatment effectiveness. For patients receiving antiresorptive therapy (e.g., bisphosphonates, denosumab), changes in resorption markers within 3–6 months after starting therapy predict medication-specific improvements in BMD and fracture risk reduction. For patients receiving anabolic therapy (e.g., teriparatide, abaloparatide), changes in formation marker values provide evidence of osteoblast stimulation and increased bone formation. In addition, usage of BTMs can improve patient adherence because measurable changes in the markers provide visible evidence of treatment effectiveness; accurate reporting of the BTM values may also improve patient motivation to remain adherent at levels of compliance [0]

5.FRACTURE PREDICTION AND RISK STRATIFICATION

Bone turnover markers (BTMs) can predict the risk of fracture independently of bone mineral density (BMD) alone. Research demonstrates, through clinical trials and meta-analyses, that elevations in levels of s-PINP and s-CTX are both linked to future risk of fracture, and that rate of bone remodeling on its own is also a strong predictor of skeletal fragility. Whereas BMD provides a snapshot of bone mass, BTMs capture dynamic skeletal alterations. With the aid of tools such as FRAX, this coupling enhances predictive value, most notably for patients with intermediate BMD or even partially assessed risk by DXA [0]. BTMs also allow for the stratification of patients into higher- or lower-risk groups, with early interventions. For instance, postmenopausal women with recurrently high s-CTX levels are at significantly higher risk of future fractures, enabling clinicians to aim prevention interventions like pharmacotherapy and fall prevention at most at risk. Early detection with BTMs enables timely initiation of interventions such as calcium and vitamin D supplementation, exercise, cessation of smoking, and relevant medications that can postpone or avoid fractures. This strategy is particularly important in the elderly, considering the high morbidity and mortality of osteoporotic fractures [0].

6.MANAGEMENT OF OSTEOPOROSIS BY BTMS

The primary objective of osteoporosis management is to sustain skeletal integrity and avoid fractures. Bone turnover markers (BTMs) yield instant measures of bone remodeling that direct therapy decisions and initial evaluation of treatment response [46]. Prevention of fracture risk is facilitated by tracking resorption markers; decreases post-antiresorptive therapy signal long-term reduction of fractures, but consistently elevated levels can signal inadequate response or compliance issues [0]. BTMs also provide information regarding bone quality, i.e., microarchitecture and

© BTS Pharma Empire All Rights Reserved

e-ISSN: 3108-3218
BTS International Advanced Pharmaceutical Sciences Journal
Vol 01 | Issue 06 | JUNE 2026 Journal homepage: www.btsempire.com
ARTICLE ID: BTS0626002

mineralization, and assist in assessing the efficacy of antiresorptive and anabolic therapies. Baseline and follow-up BTM assessments (in most cases at 3–6 months) are carried out for monitoring treatment, and allow the clinician to measure responsiveness and adjust therapy sooner if treatment is not working. Long-term monitoring ensures long-term efficacy since stable formation markers and suppressed resorption markers suggest reduced fracture risk. Overall, including BTMs into clinical practice provides more individualized treatment, and improves adherence, skeletal outcomes, and quality of life [0].

7.BTM LIMITATIONS AND CHALLENGES

Despite their usefulness in the clinic, bone turnover markers (BTMs) have several limitations. The biggest challenge is biological and preanalytical variability since BTM values depend on sample collection technique, circadian rhythm, fasting, storage, and handling as well as patient-specific factors such as age, gender, menopausal status, genetics, comorbid conditions, and lifestyle factors including diet, exercise, smoking, and alcohol consumption. This heterogeneity confounds discrimination between normal physiological variation and clinically significant change [0]. In addition, the absence of standardized assays and reference ranges precludes reproducibility. Variability in laboratory practice, reagents, calibration protocols, and population factors such as ethnicity, diet, and prevalence of disease makes interpretation challenging and emphasizes the necessity for international standardization, validated biomarkers, and age- and sex-specific reference intervals [0].

Further, clinical interpretation of BTMs is also complicated by the fact that levels are influenced by physiological as well as pathological states, such as growth, hormonal fluctuations, chronic diseases, and drugs like glucocorticoids or bisphosphonates. Heterogeneity among premenopausal compared with postmenopausal women, or the young versus older groups, further hinders analysis. Clinicians need to combine BTM findings with clinical assessment, imaging, and history to arrive at a decision. Lastly, cost, availability, and accessibility are pragmatic barriers since testing in many cases is not reimbursed by insurance and is absent from low-resource countries. Increasing laboratory capacity and designing affordable assays are necessary measures to permit equitable access and maximize the clinical utility of BTMs worldwide [0].

8. FUTURE DIRECTIONS

The future of bone turnover markers (BTMs) lies in applying dynamic metabolic information together with structural imaging to maximize osteoporosis treatment. Combing BTMs and imaging tools such as dual-energy X-ray absorptiometry (DXA) and quantitative computed tomography (QCT) could provide a more nuanced assessment of bone health, improve fracture prediction models, and allow better monitoring of individual response to treatment [0].

BTMs are also of potential use in personalized and precision medicine, where the treatment can be tailored to a patient's biomarker profile to optimize therapy, minimize side effects, and increase compliance. The significance of early identification of poor responders is high in the sense that it makes treatment changes possible that can lower fracture

© BTS Pharma Empire All Rights Reserved

e-ISSN: 3108-3218

BTS International Advanced Pharmaceutical Sciences Journal

Vol 01 | Issue 06 | JUNE 2026 Journal homepage: www.btsempire.com

ARTICLE ID: BTS0626002

risk and optimize outcomes [0]. Apart from current conventional BTMs, novel biomarkers researching collagen cross-linking, inflammatory mediators, and genetic regulation could provide bone quality information, and extend utility to disorders such as osteoarthritis, metastatic bone disease, and chronic kidney disease-mineral bone disorder. Although we have progressed in this field of research, several areas of the literature remain, such as the requirement of large longitudinal cohorts to demonstrate predictive value in multi-ethnic cohorts, an examination of the effect of serial BTM sampling on response to treatment and healthcare dollars, which further augments the rationale for BTMs in the personalized management of osteoporosis [0].

9. CONCLUSION

BTMs represent a promising and informative tool to assist in the treatment of osteoporosis patients, and give much new information about bone metabolism, treatment response, and fracture risk. They have the potential to improve fracture prediction and allow for more individualized patient-cantered treatment planning; however, increased use of BTMs is impeded by limitations such as biological variability, lack of standardized reference ranges, difficulty of interpretation, and cost and availability. The future development of BTMs with imaging technologies, investigations into new biomarkers, and advances in personalized medicine should all expand on their utility to improve care for patients. To maximize their potential in the clinic, continued efforts must be placed on standardization, reducing costs, and increasing access, while ongoing research gaps are addressed through sound clinical studies. With these developments, BTMs are likely to assume a progressively greater role in enhancing the diagnosis, management, and treatment of osteoporosis in the coming years.

ACKNOWLEDGEMENT: I would like to express my sincere gratitude to Dr. Triveni Rajagiri, Assistant Professor, Department of Pharmacy Practice, for her valuable guidance and encouragement throughout this work. I also extend my heartfelt thanks to the Principal and Management of KVSR Siddhartha College of Pharmaceutical Sciences for their continuous support.

FINANCIAL SUPPORT AND SPONSORSHIP: I did not receive any financial support from sponsors.

CONFLICTS OF INTEREST I declare that I have no conflicts of interest.

REFERENCES:

1. Aggarwal J, Modi M, Gupta RN, Pasha EH. Utility of bone turnover markers in metabolic bone diseases. Santosh University Journal of Health Sciences [Internet]. 2023 Jan 1;9(1):48–52. Available from: https://doi.org/10.4103/sujhs.sujhs_38_23

2. Zhong Y, Li J, Luo J, Chen F. Advances in bone turnover markers (PINP and CTX) in optimizing anti-resorptive and anabolic therapies against osteoporosis. PubMed [Internet]. 2022 Mar 1;32(167):149–54. Available from: https://pubmed.ncbi.nlm.nih.gov/35221001

3. Gharibzadeh S, Fahimfar N, Goudarzi S, Yarmohammadi H, Razi F, Khashayar P, et al. Contribution of bone turnover markers (BTMs) and vitamin D to bone health in Iranian elderly women. Journal of Diabetes & Metabolic Disorders [Internet]. 2024 Jun 6;23(2):1871–7. Available from:

© BTS Pharma Empire All Rights Reserved

e-ISSN: 3108-3218

BTS International Advanced Pharmaceutical Sciences Journal

Vol 01 | Issue 06 | JUNE 2026 Journal homepage: www.btsempire.com

ARTICLE ID: BTS0626002

https://doi.org/10.1007/s40200-024-01436-0

4. Ahn SH, Park SY, Kwak MK, Kim SH, Kim TY, Kim HY, et al. THU428 Association of Bone Turnover Markers Monitoring with Osteoporosis Medication adherence in Korea: a Nationwide cohort study. Journal of the Endocrine Society [Internet]. 2023 Oct 1;7(Supplement_1). Available from: https://doi.org/10.1210/jendso/bvad114.389

5. Zhong Y, Li J, Luo J, Chen F. Advances in bone turnover markers (PINP and CTX) in optimizing anti-resorptive and anabolic therapies against osteoporosis. PubMed [Internet]. 2022 Mar 1;32(167):149–54. Available from: https://pubmed.ncbi.nlm.nih.gov/35221001

6. Brouwers P, Bouquegneau A, Cavalier E. Insight into the potential of bone turnover biomarkers: integration in the management of osteoporosis and chronic kidney disease-associated osteoporosis. Current Opinion in Endocrinology Diabetes and Obesity [Internet]. 2024 May 28; Available from: https://doi.org/10.1097/med.0000000000000869

7. Kanis JA, Cooper C, Rizzoli R, Reginster J y. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporosis International [Internet]. 2018 Oct 15;30(1):3–44. Available from: https://doi.org/10.1007/s00198-018-4704-5

8. Altınsoy KE, Unat B. The role of bone turnover markers in diagnosis, monitoring, and pathological fractures of osteoporosis. Turkish Journal of Trauma and Emergency Surgery [Internet]. 2024 Jan 1;323–7. Available from: https://doi.org/10.14744/tjtes.2024.48409\

9. Messina OD, Vidal M, Torres J a M, Vidal LF, Arguissain C, Pereira RM, et al. Evidence based Latin American Guidelines of clinical practice on prevention, diagnosis, management and treatment of glucocorticoid induced osteoporosis. A 2022 update. Aging Clinical and Experimental Research [Internet]. 2022 Nov 9;34(11):2591–602. Available from: https://doi.org/10.1007/s40520-022-02261-2

10. Fuggle NR, Beaudart C, Bruyère O, Abrahamsen B, Al-Daghri N, Burlet N, et al. Evidence-Based Guideline for the management of osteoporosis in men. Nature Reviews Rheumatology [Internet]. 2024 Mar 14;20(4):241–51. Available from: https://doi.org/10.1038/s41584-024-01094-9

11. Burch J, Rice S, Yang H, Neilson A, Stirk L, Francis R, et al. Systematic review of the use of bone turnover markers for monitoring the response to osteoporosis treatment: the secondary prevention of fractures, and primary prevention of fractures in high-risk groups. Health Technology Assessment [Internet]. 2014 Feb 1;18(11). Available from: https://doi.org/10.3310/hta18110

12. Lin S, Yang F, Ling M, Fan Y. Association between bone trace elements and osteoporosis in older adults: a cross-sectional study. Therapeutic Advances in Musculoskeletal Disease [Internet]. 2022 Jan 1;14. Available from: https://doi.org/10.1177/1759720x221125984

13. Gazoni FM, Civile VT, Atallah ÁN, Santos FC, Trevisani VFM. Intravenous zoledronate for postmenopausal women with osteopenia and osteoporosis: a systematic review and metanalysis. Sao Paulo Medical Journal [Internet]. 2023 Jan 1;141(6). Available from:

© BTS Pharma Empire All Rights Reserved

e-ISSN: 3108-3218

BTS International Advanced Pharmaceutical Sciences Journal

Vol 01 | Issue 06 | JUNE 2026 Journal homepage: www.btsempire.com

ARTICLE ID: BTS0626002

https://doi.org/10.1590/1516-3180.2022.0480.r1.27032023

14. Voulgaridou G, Papadopoulou SK, Detopoulou P, Tsoumana D, Giaginis C, Kondyli FS, et al. Vitamin D and Calcium in Osteoporosis, and the Role of Bone Turnover Markers: A Narrative Review of Recent Data from RCTs. Diseases [Internet]. 2023 Feb 8;11(1):29. Available from: https://doi.org/10.3390/diseases11010029

15. Sangtarash F, Shadmehr A, Choobsaz H, Fereydounnia S, Sadeghi A, Jung F, et al. Effects of resistance training on microcirculation of bone tissue and bone turnover markers in postmenopausal women with osteopenia or osteoporosis: A systematic review. Clinical Hemorheology and Microcirculation [Internet]. 2025 Jan 12;89(2):171–80. Available from: https://doi.org/10.1177/13860291241291411

16. Rand MS, Eiken PA, Jørgensen NR. Clinical application of bone turnover markers in osteoporosis. Ugeskrift for Læger [Internet]. 2024 Jan 29;186(5):1–10. Available from: https://doi.org/10.61409/v07230432

17. Rösch G, Zaucke F, Jenei-Lanzl Z. Autonomic nervous regulation of cellular processes during subchondral bone remodeling in osteoarthritis. AJP Cell Physiology [Internet]. 2023 Jun 19;325(2):C365–84. Available from: https://doi.org/10.1152/ajpcell.00039.2023

18. Kini U, Nandeesh BN. Physiology of bone formation, remodeling, and metabolism. In: Springer eBooks [Internet]. 2012. p. 29–57. Available from: https://doi.org/10.1007/978-3-642-02400-9_2

19. Hsiao CY, Chen TH, Chu TH, Ting YN, Tsai PJ, Shyu JF. Calcitonin induces bone formation by increasing expression of WNT10B in osteoclasts in Ovariectomy-Induced osteoporotic rats. Frontiers in Endocrinology [Internet]. 2020 Sep 8;11. Available from: https://doi.org/10.3389/fendo.2020.00613

20. Zhang B, Li L, Zeng H, Xu X, Wang R, Chen M, et al. Association between bone turnover markers and the risk of imminent recurrent osteoporotic fracture. Medicine International [Internet]. 2022 Jul 28;2(4). Available from: https://doi.org/10.3892/mi.2022.49

21. Johansson H, Odén A, Kanis JA, McCloskey EV, Morris HA, Cooper C, et al. A Meta-Analysis of reference Markers of bone turnover for International [Internet]. 2014 Mar 4;94(5):560–7. Available from: https://doi.org/10.1007/s00223-014-9842-y

22. Burch J, Rice S, Yang H, Neilson A, Stirk L, Francis R, et al. Systematic review of the use of bone turnover markers for monitoring the response to osteoporosis treatment: the secondary prevention of fractures, and primary prevention of fractures in high-risk groups. Health Technology Assessment [Internet]. 2014 Feb 1;18(11). Available from: https://doi.org/10.3310/hta18110

23. Eastell R, Hannon RA. Biomarkers of bone health and osteoporosis risk. Proceedings of the Nutrition Society [Internet]. 2008 Apr 15;67(2):157–62. Available from: https://doi.org/10.1017/s002966510800699

24. Szulc P, Naylor K, Hoyle NR, Eastell R, Leary ET. Use of CTX-I and PINP as bone turnover markers: National Bone Health Alliance recommendations to standardize sample handling and patient preparation to reduce pre-analytical variability. Osteoporosis International [Internet]. 2017 Jun 19;28(9):2541–56. Available from: https://doi.org/10.1007/s00198-017-4082-4

© BTS Pharma Empire All Rights Reserved

e-ISSN: 3108-3218

BTS International Advanced Pharmaceutical Sciences Journal

Vol 01 | Issue 06 | JUNE 2026 Journal homepage: www.btsempire.com

ARTICLE ID: BTS0626002

25. Garnero P, Vergnaud P, Hoyle N. Evaluation of a fully automated serum assay for total N-Terminal propeptide of type I collagen in postmenopausal osteoporosis. Clinical Chemistry [Internet]. 2007 Nov 13;54(1):188–96. Available from: https://doi.org/10.1373/clinchem.2007.094953

26. Brescia V, Lovero R, Fontana A, Zerlotin R, Colucci SC, Grano M, et al. Reference Intervals (RIs) of the bone turnover markers (BTMs) in Children and Adolescents: A Proposal for Effective use. Biomedicines [Internet]. 2024 Dec 27;13(1):34. Available from: https://doi.org/10.3390/biomedicines13010034

27. Kuo TR, Chen CH. Bone biomarker for the clinical assessment of osteoporosis: recent developments and future perspectives. Biomarker Research [Internet]. 2017 May 8;5(1). Available from: https://doi.org/10.1186/s40364-017-0097-4

28. Feng XJ, Zhou WJ, Zhang J, Zhang YD, Yu XN, Yu F. [Research progress of novel bone turnover markers in osteoporosis]. PubMed [Internet]. 2024 Dec 6;58(12):2045–55. Available from: https://pubmed.ncbi.nlm.nih.gov/39710487

29. Kim BJ, Lee SH, Koh JM. Potential biomarkers to improve the prediction of osteoporotic fractures. Endocrinology and Metabolism [Internet]. 2020 Mar 19;35(1):55–63. Available from: https://doi.org/10.3803/enm.2020.35.1.55

© BTS Pharma Empire All Rights Reserved